BioCentury
ARTICLE | Clinical News

Alagebrium: Phase II started

May 19, 2008 7:00 AM UTC

Synvista began the double-blind, placebo-controlled, U.S. Phase II BREAK trial to evaluate 20 mg of oral alagebrium given twice daily for 6 months in 160 patients. ...